Research Article
Preparation, Characterization, and Preliminary Imaging Study of [188Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis
Table 2
The biodistribution of [188Re]Re-IBA in mice (n = 4).
| Tissue | %ID/g (%) | 1 h | 3 h | 6 h | 24 h | 48 h |
| Heart | 0.488 ± 0.179 | 0.293 ± 0.118 | 0.199 ± 0.049 | 0.045 ± 0.012 | 0.019 ± 0.010 | Liver | 1.100 ± 0.165 | 0.794 ± 0.133 | 0.526 ± 0.087 | 0.122 ± 0.042 | 0.038 ± 0.020 | Spleen | 0.952 ± 0.336 | 0.475 ± 0.135 | 0.296 ± 0.108 | 0.189 ± 0.052 | 0.046 ± 0.009 | Lung | 1.297 ± 0.661 | 0.784 ± 0.196 | 0.506 ± 0.104 | 0.138 ± 0.037 | 0.040 ± 0.020 | Kidney | 5.894 ± 1.648 | 3.140 ± 0.799 | 2.763 ± 0.731 | 0.913 ± 0.173 | 0.399 ± 0.153 | Stomach | 2.928 ± 0.851 | 2.801 ± 0.560 | 1.741 ± 0.368 | 0.098 ± 0.036 | 0.047 ± 0.019 | Thyroid gland | 0.594 ± 0.201 | 0.449 ± 0.171 | 0.399 ± 0.082 | 0.115 ± 0.036 | 0.070 ± 0.019 | Small intestine | 0.898 ± 0.494 | 0.597 ± 0.214 | 0.608 ± 0.192 | 0.078 ± 0.013 | 0.033 ± 0.010 | Blood | 1.869 ± 0.665 | 0.785 ± 0.220 | 0.496 ± 0.207 | 0.058 ± 0.013 | 0.031 ± 0.009 | Brain | 0.072 ± 0.023 | 0.056 ± 0.010 | 0.045 ± 0.011 | 0.024 ± 0.013 | 0.009 ± 0.002 | Femur | 5.989 ± 1.680 | 7.105 ± 1.901 | 7.724 ± 2.292 | 6.177 ± 2.163 | 5.239 ± 2.029 | Muscle | 0.550 ± 0.251 | 0.344 ± 0.143 | 0.220 ± 0.124 | 0.051 ± 0.020 | 0.016 ± 0.005 | Gonad | 0.878 ± 0.426 | 0.611 ± 0.095 | 0.303 ± 0.141 | 0.059 ± 0.032 | 0.029 ± 0.009 | Femur/heart | 12.278 | 24.214 | 38.835 | 137.083 | 270.814 | Femur/liver | 5.443 | 8.949 | 14.694 | 50.645 | 136.914 | Femur/muscle | 10.880 | 20.664 | 35.182 | 121.910 | 325.483 |
|
|
The percentage injection dose rate per gram of tissue (%ID/g) is expressed as mean ± standard deviation ( ± s). |